T he FGAs are a group of drugs with the common pharmacological action of D2 blockade. D2 blockade offers impressive (relative to placebo) but limited therapeutic benefit in the treatment of acute psychotic exacerbations and in the prevention of psychotic relapse. Most patients have incomplete relief of psychopathology. 1 However, the FGAs are a pharmacologically disparate group, ranging from relatively clean D2 blocking agents (for example, perphenazine) to agents with multiple additional pharmacological actions (for example, thioridazine) that underwrite an array of unnecessary side effects. One might surmise that an FGA that produced severe anticholinergic toxicities, distressing autonomic side effects (for example, sexual dysfunction and orthostatic hypotension), and disproportionate prolactin elevations would have been rarely prescribed. In fact, thioridazine was the most widely prescribed FGA in the United States for a time; it was sedating and had fewer propensities for EPSEs. It was widely used for children who, when taking it, could review the same schoolwork over and over again and experience each page's content as new and exciting each time they read it. It was also widely used in the elderly (for example, someone my age) in whom cholinergic neurons are disappearing at alarming rates. And so it goes.
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The only useful thing that FGAs do is block D2 receptors. When about 60% to 70% D2 blockade is achieved, mesolimbic dopamine-releasing neurons begin a transition into depolarization block, a process that underlies therapeutic recovery. The induction of this process is a yes or no phenomenon, not a graded phenomenon, an on-off switch rather than a rheostat. More pressure on the switch (that is, higher doses) does not hasten the process or intensify it. 1 However, clinicians treated an FGA dose as a rheostat, a throttle, a gas pedal (despite study after study proving the incorrectness of this approach) in futile efforts to obtain more therapeutic benefit than the FGAs had to offer, and accepted unnecessary coarse EPSE. They added anticholinergic drugs to hide these EPSE, accepting unnecessary dry mouth, blurred vision, constipation, and memory impairment, and leaving patients at high risk for TD.
To use FGAs well, clinicians must tailor doses to the achievement of 60% to 70% D2 blockade. This can be done grandly with positron emission tomography scanning or hormone challenge procedures. Or, this can be done humbly by examining patients for muscle tone and fluidity of movement prior to starting an FGA, and then repeating this examination as dose is slowly increased. The examination takes less than 2 minutes. When a slight increase in bradykinesia-rigidity is induced, 60% to 70% D2 blockade has been achieved. As much therapeutic response as an individual patient will garner from an FGA will unfold over the next few weeks. Higher doses bring coarse EPSE and do not hasten or enhance therapeutic response. 2 If therapeutic response is inadequate, a different approach (for example, clozapine), not higher doses, is needed.
Consider if clinicians treated every patient with epilepsy with diphenylhydantoin 300 mg daily, many patients would do well, some would have inadequate brain levels and unnecessary seizures, and some would have toxic ataxias. If these same clinicians instead repeatedly examined patients and adjusted diphenylhydantoin doses upward or downward to the appearance of mild nystagmus or ataxia, more patients would do well and few if any would be under-or overdosed. If clinicians treated every patient with psychosis with an FGA at doses that produced mild bradykinesia-rigidity (instead of at some standard dose), more would do well and few if any would be under-or overdosed. Unfortunately, the use of such a fundamental pharmacological principle never became routine practice among clinicians prescribing FGAs.
If we are going to address the question of whether FGAs are better or worse than the SGAs, we must decide first if we refer to the FGAs as they were used, that is, badly, or the FGAs as they should be used. We must decide whether the comparator FGA is sensibly chosen and sensibly dosed. We chose perphenazine as the FGA comparator in the CATIE 3 because we believed perphenazine offered the best package of therapeutic benefit relative to side effects among the FGAs. 4, 5 We restricted the dose to a maximum of 32 mg daily. Only olanzapine among the SGAs evidenced superiority over perphenazine in this dose range.
The SGAs available in the United States are a group of drugs with the common pharmacological mechanisms of D2 blockade and 5-HT 2 blockade. The addition of 5-HT 2 blockade reduces (rather than hides) EPSE and lessens the subjective misery associated with treating psychosis with excessive doses of FGAs. As with the FGAs, most patients treated with the SGAs have incomplete relief of psychopathology.
The 5-HT 2 blockade attenuates objective EPSE and the associated subjective distress, whatever level of D2 blockade is achieved. If clinicians use unnecessarily high doses of SGAs, patients suffer less than if clinicians use unnecessarily high doses of FGAs. In contrast to the intuitive expectation that more of a medication will be better, FGAs fared better in comparisons with SGAs when lower doses of the FGAs were used; the so-called advantages of SGAs in protecting patients from unwise clinicians' behaviour is lost 6 when FGAs are used sensibly.
The SGAs also are a pharmacologically disparate group. In individual studies, reviews, and meta-analyses, there is evidence that olanzapine is more efficacious and effective than FGA and SGA comparators 7 ; for example, in CATIE 3 and CUtLASS 8 patients on olanzapine continued on treatment with this agent longer than did patients on other antipsychotic medications. There is conflicting evidence regarding the relative efficacy and effectiveness of risperidone and FGA comparators. Aripiprazole, quetiapine, and ziprasidone are not more efficacious or effective than FGA comparators.
Olanzapine and quetiapine, and to a lesser degree risperidone, produce weight gain, insulin resistance, and elevations in non-HDL cholesterol and inflammatory markers, all of which lead to increased risk for diabetes mellitus and cardiovascular morbidity and mortality. Since these agents became available in the mid-1990s, the incidence of diabetes mellitus among patients with psychoses has accelerated, and the disparities in life expectancies between these patients and the general population has widened. An argument can be made that these medications should only be prescribed by clinicians competent to recognize and manage (for example, with metformin and a statin) their metabolic side effects.
One might surmise that an SGA with no evidence for superior efficacy or efficaciousness, substantial metabolic side effects (weight gain, insulin resistance, elevations in non-HDL cholesterol, and inflammatory markers), and anticholinergic and sedating effects would be rarely prescribed. In fact, quetiapine is the most widely prescribed SGA; it is sedating and has no propensities for EPSE. And so it goes.
If we are going to address the question of whether the SGAs are better or worse than the FGAs, we must first decide if the comparator SGA is sensibly chosen and used. An argument can be made to select olanzapine as champion (for optimal efficacy), with co-administration of metformin to reduce weight gain and insulin resistance, and the addition of simvastatin if non-HDL cholesterol is elevated. An argument can also be made to select aripiprazole (for optimal tolerability), although there is no reason to hope for an efficacy advantage with this agent. We in the STN-the continued CATIE infrastructure-are presently undertaking a comparison of these agents with perphenazine at doses adjusted to mild bradykinesia-rigidity.
Many patients with severe and persistent mental illnesses may best be served with a long-acting injected antipsychotic preparation. The STN is also currently undertaking a comparison of restricted-dose fluphenazine decanoate and risperidone microspheres.
Clozapine is in a class by itself, and offers improved efficacy and effectiveness for many patients who fail to respond to the FGAs or SGAs. Its use requires organized monitoring and clinicians comfortable with managing risk for agranulocytosis, myocarditis, seizures, and metabolic side effects. Unfortunately, it remains underused. And so it goes.
In the present economic climate, judgment as to what is better will include consideration of financial costs. Many patients do well on perphenazine 8 to 24 mg daily, without coarse EPSE or metabolic side effects or prolactin elevations, and at a cost of 1/100 of an SGA. It is better that these patients not be on an SGA. For patients who do not get adequate therapeutic benefit from perphenazine, a switch to olanzapine or clozapine may be better, and for patients who are exquisitely sensitive to EPSE and who cannot tolerate perphenazine, a switch to quetiapine or olanzapine may be better. 9 However, if we use these SGAs or clozapine we must practice medicine or engage a colleague who will do that for us. 
Joseph P McEvoy

SGAs Do Offer Certain Advantages Over FGAs
R evolutions in medicine are few and far between. Instead, we usually see incremental improvements. Initially, the mental health community hoped that SGAs would be a revolution over the older FGAs. With the recent publication of the CATIE 1 and CUtLASS 2 trials, it has become clear that this is not the case. However, we must be cautious not to draw broad conclusions from these studies and risk discounting the benefits of the newer antipsychotics altogether. Other welldesigned studies demonstrate improved tolerability and modestly improved efficacy of SGAs over FGA [3] [4] [5] and this body of evidence should not be discarded. The SGAs remain an important incremental step forward in the treatment of schizophrenia and should continue as first-line medications until a major innovation arrives.
Most of the backlash against the SGAs has come from analysis of CATIE as well as its British counterpart, CUtLASS. These studies demonstrate that in real-world situations, the newer medications do not fare as well as they do in traditional clinical trials. However, both studies have important limitations. The findings and limitations of CATIE have been reviewed extensively elsewhere 6 ; however, we will discuss some key issues.
First, patients in CATIE were a very particular group and do not necessarily represent all patients with schizophrenia. Many patients were enrolled in CATIE presumably because of dissatisfaction with their current treatment; about 60% of these patients were taking SGAs before enrolment and patients had a mean PANSS score of 76 at entry, indicating that they were, on average, moderately ill. Some were likely partially nonadherent. As well, FEP patients were specifically excluded. CATIE showed that for this population, the time to discontinuation of all SGAs except olanzapine was equivalent to perphenazine. Therefore, it is erroneous to assume that this conclusion applies to all patients with schizophrenia, especially FEP patients and those who are fully treatment adherent.
Second, CATIE did not compare all FGAs to SGAs; it compared SGAs to perphenazine, a single mid-potency FGA. Perphenazine was chosen specifically because it is not haloperidol and was assumed to be better tolerated. Perphenazine has an active metabolite with a pharmacological profile more similar to SGA agents. 7 Therefore, it is not possible to conclude that other FGAs would have performed similarly to perphenazine and that time to discontinuation of other FGAs would have been equivalent to SGAs.
Third, it is misleading to draw conclusions regarding the side effect profiles of the different medications because in CATIE there was no monitoring for medication adherence. An unexpected finding in CATIE was that although a greater number of patients stopped the FGA owing to neurological side effects, objective ratings of EPS showed no difference between groups. Some have questioned whether this implies that SGAs have reduced EPS, compared with FGAs, when FGAs are dosed appropriately. There is a caveat to this argument: adherence to antipsychotic medications in patients with schizophrenia can be as low as 30% to 40%. 8 Parkinsonism and akathisia are more commonly temporary side effects, while weight gain and metabolic changes are more commonly long-term side effects. Perhaps the lack of observed EPS can be explained by low or partial medication adherence. Patients not taking the prescribed dose would be unlikely to show neurological side effects on examination.
The major limitation of the CUtLASS trial is that clinicians were allowed to choose between SGAs and FGAs resulting in too few patients taking each medication to compare specific drugs. Instead, investigators had to compare the class of SGAs to FGAs. This assumes that all medications in the class are similar in efficacy and tolerability. This is unlikely, as a meta-analysis of all randomized trials has shown larger effect sizes for clozapine, risperidone, amisulpride and olanzapine than other SGAs such as quetiapine. 4 Grouping all SGAs together may reduce or even eliminate this difference.
Although it is important to consider the results of the 2 large effectiveness trials, in several recently published metaanalyses, SGAs have shown benefits over FGAs with respect to reduced dropouts, improved cognition, and reduced movement disorders. Some have also shown improved efficacy. 4, 9 A low dropout rate with an antipsychotic can be seen as one key measure of a medication's clinical usefulness. It implies both adequate effectiveness and tolerability. A recent meta-analysis showed that SGAs have a clinically significant lower dropout rate than FGAs when given in flexible dose ranges. In long-term studies, they found the number needed to treat with SGAs to prevent a dropout was 6 patients. 3 The investigators also comment that this finding cannot be accounted for by publication bias as most unpublished trials actually favour SGAs in this regard.
Cognitive deficits in schizophrenia are strongly linked to impairments in social and occupational functioning and there is evidence that SGAs are superior to FGAs at improving cognition. In a meta-analysis of trials examining improvements in cognition with antipsychotics, Woodward et al 10 showed that treatment with SGAs led to greater improvements in cognition than with FGAs, though the effect size was modest. Some authors have argued that benefits seen with SGAs owe to investigators using overly high doses of haloperidol in some studies. However, it appears that only very high doses of haloperidol (around 25 mg/day) have any significant deleterious effects on cognition, and there is no difference in cognitive improvement seen between studies with SGAs that used lower (<10 mg/day) or higher (>10 mg/day) doses of haloperidol as the comparator. 11 Therefore, the cognitive improvement seen with SGAs cannot only be attributed to the effects of overdosing FGAs.
It is well known that SGAs induce fewer movement disorders than FGAs. Parkinsonian symptoms and TD cause important functional disability in some patients and contribute significantly to the stigma associated with chronic mental illness. 12 In CATIE, 8% of patients discontinued perphenazine owing to EPS, compared with 2% to 4% for the SGAs. 1 Additionally, studies examining incidence of TD in adults after 1 year of treatment have generally found that olanzapine and risperidone induce TD in less than 1% of patients, whereas conventional antipsychotics induce TD in 3% to 5%. 5 Certain SGAs appear to be more efficacious than FGAs. Geddes et al 9 showed that some SGAs, namely, clozapine, risperidone, amisulpride, and olanzapine are more efficacious than FGAs, but their benefit disappeared when trials comparing them with doses of haloperidol of more than 12 mg were excluded from the analysis. Hence they hypothesized that if FGAs were dosed appropriately, their efficacy would be equivalent to SGAs. The choice by Geddes et al 9 to exclude studies using higher doses of haloperidol rests on the theory that higher haloperidol doses are less efficacious and favour the SGAs. The validity of this assumption has been called into question and subsequent analysis failed to show any decrease in haloperidol efficacy when it was used in higher doses in clinical trials. 4 Therefore, there is no basis to exclude trials comparing SGAs with higher doses of haloperidol and the findings that certain SGAs are more efficacious appears real. It is important to reinforce that SGAs are not all equivalent; they have important differences in side effect profiles and some demonstrate superior effectiveness. This allows for improved personalization of treatment. For example, clozapine has shown improved effectiveness over other antipsychotics. In the CATIE Clozapine Trial, patients who failed a previous antipsychotic and switched to clozapine remained on the drug, on average, for 10 months, 3 times longer than those who switched to a different SGA. 13 Whereas the side effect profiles of FGAs are similar for agents of similar potencies, the side effect profiles of SGAs differ. For example, quetiapine and clozapine have particularly low incidences of EPS, and ziprasidone causes less weight gain than other antipsychotics, including FGAs. With SGAs it is possible to individualize treatment using medications that have a risk-benefit profile acceptable to a given patient.
The main concerns about some SGAs are their propensity to cause weight gain and metabolic abnormalities. Most of the data citing greater weight gain with SGAs such as olanzapine and risperidone come from short-term studies with patients previously treated with psychotropic medication. In contrast, a recent 1-year randomized trial comparing haloperidol, olanzapine, and risperidone in drug-naive patients showed that although patients gained weight more quickly on SGAs, after 1 year this difference disappeared; all patients had gained about 10 kg. 14 Perhaps the weight gain seen in short-term trials with SGAs is also a problem with some FGAs when patients are treated for longer periods. The researchers further note that the propensity for SGAs to cause more weight gain initially would put them at a disadvantage in trials with high dropout rates that use last observation carried forward analysis. This study suggests that FGAs are not weight-neutral, especially when treating drug-naive patients for extended periods of time.
In conclusion, though the SGAs are not the revolution they were hoped to be, there is evidence that they do possess some benefits over FGAs. Specifically, patients taking SGAs show lower dropout rates, fewer movement disorders, and improved cognition; additionally, certain SGAs, notably clozapine, also have better efficacy than FGA comparators. CATIE and CUtLASS were important in attenuating the mental health community's overenthusiasm with the newer antipsychotics, but these effectiveness trials have key limitations and should not carry more weight than systematic meta-analyses. Because of their previously mentioned benefits, SGAs should remain the first-line medications for the treatment of schizophrenia. . . do not necessarily represent all patients with schizophrenia." We worked in CATIE to recruit a broadly representative, inclusive sample that was geographically and ethnically diverse and treated in a wide range of clinical care systems. "Many patients were enrolled in CATIE presumably because of dissatisfaction with their current treatment"; one presumes this to be true of most treatment trials. However, dissatisfaction was not an inclusion criterion.
"Some were likely partially nonadherent." Pills cannot be compared among patients who do not take pills. CATIE excluded patients currently treated with a long-acting injected antipsychotic preparation following a history of nonadherence to oral medications. When patients with comorbid substance use disorders (a group characterized by frequent nonadherence) were excluded from the CATIE analyses, the advantages for olanzapine, compared with perphenazine, and the lack of advantages for the other SGAs, become more clearly apparent. 1 FEP patients were specifically excluded from CATIE. Two blinded studies 2,3 comparing risperidone to haloperidol and one blinded study 4 comparing olanzapine to haloperidol in FEP patients spark little enthusiasm for the SGAs as first-line treatments. The Treatment of Early-Onset Schizophrenia Spectrum Disorders study 5 found no advantage for olanzapine or risperidone over mid-potency molindone in early onset psychosis.
Dr Zigman and Dr Margolese suggest that we did not find differences in EPSE ratings between perphenazine and the SGAs because of nonadherence. We chose perphenazine because it offered the best package of therapeutic benefit relative to side effects among the FGAs, 6, 7 and we restricted its available dose range. We worked to minimize coarse EPSE; we did not "conclude that other FGAs would have performed similarly to perphenazine." A small percentage of sensitive patients did not tolerate even restricted-dose perphenazine; these patients were subsequently more successfully treated with quetiapine or olanzapine than with risperidone, in keeping with the EPSE liabilities of these SGAs. 8 Whatever nonadherence occurred in CATIE did not obscure the weight and metabolic liabilities of some SGAs. Dr Zigman and Dr Margolese cite Perez-Iglesias et al 9 who found no differences in weight gain among FEP patients treated with haloperidol, risperidone, or olanzapine. Perez-Iglesias et al 10 also report no differences across these 3 antipsychotic medications in insulin levels and lipid measures. Remarkable, but at odds with other FEP studies, lasting a year or more. 2, 3, 11, 12 "SGAs should remain the first-line medications for the treatment of schizophrenia." What exactly does first line imply? Am I a bad person because I treat many new patients, including FEP patients, with low-dose fluphenazine, and transition those who respond and who tolerate fluphenazine to fluphenazine decanoate (6.25 to 12.5 mg intramuscular every 2 weeks). These patients have no coarse EPSEs, no prolactin elevations or sexual side effects, no weight gain or metabolic effects, and their drug costs are less than US$100 per year. If patients do not tolerate fluphenazine, I switch to an SGA. If patients do not garner therapeutic benefit, I switch to olanzapine and then clozapine. Neither the FGAs nor the SGAs are homogeneous sets. We probably do better individually tailoring these nonhomogeneous medications to the nonhomogeneous patients we treat.
Movement Disorders Remain a Very Important Side Effect With FGAs, and FGAs Are Not Equivalent to SGAs, Even When Carefully Dosed
D r McEvoy raises some interesting arguments regarding
why FGAs may be a better choice for many patients with schizophrenia. However, the crux of Dr McEvoy's argument is that FGAs are frequently used improperly and if FGAs are dosed appropriately, they are essentially equivalent to SGAs. This is not entirely accurate and is somewhat idealistic.
First, we are still not clear that all antipsychotics are equally effective. As CATIE's primary outcome measure was discontinuation of medication for any reason, it is difficult to know what to make of the finding that about two-thirds of patients in all groups chose to discontinue or switch antipsychotics by the end of the trial. We believe that the more appropriate conclusion from CATIE is not that all antipsychotics are equally effective, but that patients will decide to change or discontinue their antipsychotic given the opportunity.
Second, even if dosed properly, FGAs are still more likely to cause EPSs and TD than SGAs. It is easy to neglect TD when considering only outcomes of short-term clinical trials. Additionally, remember that CATIE excluded perphenazine for patients who had TD. This lack of random assignment may have biased results in favour of the FGA perphenazine. As we described, TD can be highly stigmatizing and, in some patients, debilitating and irreversible. Considering that most patients with psychotic disorders need to take antipsychotics on a long-term basis, the lowered incidence of TD associated with SGAs decreases the number of patients who will develop TD. In this regard, SGAs are clearly superior to FGAs.
Finally, there is a narrow therapeutic window in which FGAs can be used with mild EPS and acceptable antipsychotic effects; outside of clinical trial conditions, it can be challenging to dose FGAs properly and keep them in the therapeutic window. Patients with schizophrenia frequently miss doses, or take other medications and (or) illicit drugs that alter the metabolism of antipsychotics. This can lead to either accumulation of antipsychotic and associated EPSs or reduced antipsychotic levels and relapse of psychotic symptoms.
Therefore, it is helpful if patients can tolerate larger dose ranges without unacceptable side effects or loss of therapeutic effect. Fine dose adjustment by clinical examination is also not always feasible for logistical reasons such as missed appointments and agitated or noncooperative patients. Additionally, many health care systems are encouraging the transfer of stabilized patients to general practitioners, who are not experts in finely titrating antipsychotics into the optimal therapeutic window. Although fine adjustments of antipsychotic dosing may work for some patients, in real-world conditions it is often impractical.
Even before the introduction of SGAs, patients with schizophrenia had increased mortality from physical health problems, compared with the general population. In recent years, the flipside of the metabolic syndrome problem has been that, as mental health professionals, we have become more attentive to the physical health of our patients. Mental health professionals have: been more insistent that psychiatric patients are followed concurrently by a general practitioner; and started walking groups; encouraged smoking cessation; started weighing patients regularly and monitoring for markers of the metabolic syndrome. In short, they have started taking better care of patients.
Even in the post-CATIE era, and even with our current knowledge of the metabolic effects of SGAs, only 4% of surveyed health care professionals stated that they would choose to take an FGA if they themselves needed to take an antipsychotic. 1 Despite the financial costs, should we not give the same choice to our patients?
